CLD-501 / Calidi Biotherap - LARVOL DELTA

Calidi Biotherapeutics…announced that…abstracts showcasing the Company’s RedTail platform have been accepted for online publication at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) - "The Company will also present preclinical data on CLD-501, the lead compound from its in situ T-cell engager ('TCE') approach. CLD-501 is a systemically delivered virotherapy designed to selectively target tumors and simultaneously enable the high-level in situ expression of a TROP-2 TCE and IL-15 SA."

Preclinical • Solid Tumor

Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026 (GlobeNewswire) - "The Company expects to file an IND for CLD-401 by the end of 2026. Data presented at the AACR meeting showcased RedTail viruses that can express both a functional T-cell engager, capable of binding targeted solid tumor cells, and IL-15 SA at high concentrations, allowing for simultaneous T-cell activation and high expression in situ of a T-cell engager....By remodeling the TME and driving T-cell activation in concert with expression of a T-cell engager, RedTail is designed to overcome these historical limitations....The Company is developing CLD-501, a lead candidate targeting TROP2, a cell-surface glycoprotein."

IND • New molecule • Preclinical • Solid Tumor